Loading…
Olema Pharmaceuticals, Inc. is projected to rise to $11.84 by 2027, a +3% move from its current price of $11.45. OLMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $11.13 | $11.46 | $11.80 | +0.07% |
| Aug 3 | $11.00 | $11.47 | $11.95 | +0.13% |
| Aug 4 | $10.91 | $11.47 | $12.07 | +0.20% |
| Aug 5 | $10.83 | $11.48 | $12.17 | +0.26% |
| Aug 6 | $10.76 | $11.49 | $12.26 | +0.33% |
| Aug 7 | $10.70 | $11.50 | $12.34 | +0.40% |
| Aug 8 | $10.65 | $11.50 | $12.42 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.65 | $11.50 | $12.42 | +0.46% |
| Week 2 | $10.36 | $11.56 | $12.89 | +0.93% |
| Week 3 | $10.16 | $11.61 | $13.27 | +1.40% |
| Week 4 | $10.00 | $11.66 | $13.61 | +1.86% |
| Week 5 | $9.86 | $11.72 | $13.92 | +2.34% |
| Week 6 | $9.75 | $11.77 | $14.21 | +2.81% |
| Week 7 | $9.65 | $11.83 | $14.50 | +3.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc.
in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biotechnology company focused on therapies for women’s cancers, with palazestrant as its lead candidate in Phase 3 trials for ER+/HER2- breast cancer. The stock is currently priced at $12.01 with a market capitalization of $1.05B and a rank of 2371.
The near- to longer-term forecast spans several years with a steady path of potential upside across multiple milestones.
A major floor 30.3% below — a decisive break under it would weaken the trend.
The nearest floor, 16.9% below — buyers have tended to step in here.
The nearest ceiling, 11.5% above — a clean break opens room to run.
A major ceiling 46.9% above — clearing it would confirm fresh momentum.
Key OLMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OLMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.62 | Sell | $11.57 | Sell |
| MA 10 | $11.60 | Sell | $11.61 | Sell |
| MA 20 | $11.79 | Sell | $11.63 | Sell |
| MA 50 | $11.53 | Sell | $12.15 | Sell |
| MA 100 | $13.26 | Sell | $13.64 | Sell |
| MA 200 | $17.45 | Sell | $14.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.33 | Neutral |
| Stoch RSI (14) | 46.62 | Neutral |
| CCI (20) | -70.13 | Neutral |
| Williams %R (14) | -59.57 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -3.13 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 40.43 | Neutral |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | 0.22 | Buy |
| Ultimate (7,14,28) | 49.31 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 11.50 | Sell |
| ADX (14) | 10.55 | Neutral |
| ATR (14) | 0.32 | Info |
The near-term technical posture is bullish on the surface, with an RSI of 50. The stock trades around the 50-day moving average of $11.72 and below the 200-day moving average of $17.43, indicating mixed trend momentum. A key support level is at $9.19 and a resistance at $12.77, providing a defined trading band in the current setup.
The 30-day trading range is from $9.95 to $14.49, illustrating recent volatility within a relatively tight ceiling.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.19 | $11.45 | $15.20 | 0% | Neutral | |
| $9.39 | $11.84 | $15.83 | +3% | Neutral | |
| $9.07 | $11.79 | $16.39 | +3% | Neutral | |
| $9.91 | $13.22 | $18.96 | +15% | Neutral | |
| $10.14 | $13.82 | $20.33 | +21% | Bullish | |
| $11.64 | $16.19 | $24.37 | +41% | Bullish | |
| $13.06 | $18.51 | $28.42 | +62% | Bullish | |
| $13.04 | $18.81 | $29.41 | +64% | Bullish | |
| $12.98 | $19.05 | $30.29 | +66% | Bullish | |
| $12.58 | $18.75 | $30.28 | +64% | Bullish | |
| $17.73 | $28.42 | $48.98 | +148% | Bullish | |
| $27.67 | $50.36 | $95.33 | +340% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.19 | $11.45 | $14.17 | +0.00% |
| September 2026 | $10.33 | $12.25 | $14.95 | +6.98% |
| October 2026 | $10.18 | $12.16 | $15.01 | -0.73% |
| November 2026 | $9.93 | $11.93 | $14.86 | -1.88% |
| December 2026 | $10.02 | $12.10 | $15.20 | +1.42% |
Click any year to see its month-by-month OLMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect OLMA to range from $9.19 to $15.20 through 2026. The $11.45 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The OLMA price prediction for 2027 points to an average of $11.84 (low $9.39, high $15.83) — a potential gain of +3% on today's $11.45. A consolidation phase looks the most probable path here.
In 2028, OLMA is projected to trade between $9.07 and $16.39, averaging $11.79 — a potential gain of +3% from today's $11.45. That is 0% versus the projected 2027 average. Price action looks broadly range-bound.
Olema Pharmaceuticals, Inc.'s 2029 outlook centres on $13.22, within a $9.91 to $18.96 range. That is up +12% on the projected 2028 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, OLMA could reach as high as $20.33, with a base case around $13.82 and support toward $10.14 — roughly +21% from $11.45. Momentum favours further upside here.
Expect OLMA to range from $11.64 to $24.37 through 2031. The $16.19 average target implies a +41% move from current prices. That is up +17% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The OLMA price prediction for 2032 points to an average of $18.51 (low $13.06, high $28.42) — a potential gain of +62% on today's $11.45. Momentum favours further upside here.
In 2033, OLMA is projected to trade between $13.04 and $29.41, averaging $18.81 — a potential gain of +64% from today's $11.45. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Olema Pharmaceuticals, Inc.'s 2034 outlook centres on $19.05, within a $12.98 to $30.29 range. That is up +1% on the projected 2033 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2035, OLMA could reach as high as $30.28, with a base case around $18.75 and support toward $12.58 — roughly +64% from $11.45. Buyers look set to stay in control over this stretch.
Expect OLMA to range from $17.73 to $48.98 through 2040. The $28.42 average target implies a +148% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The OLMA price prediction for 2050 points to an average of $50.36 (low $27.67, high $95.33) — a potential gain of +340% on today's $11.45. Buyers look set to stay in control over this stretch.
Investing $1,000 in OLMA today (≈ 87.336245 OLMA) could be worth
$4,398.41
+$3,398.41 (+340%) by 2050 · US Dollar
Based on the average projected OLMA price of $50.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OLMAwould be worth at today's price.
$1,000 invested in OLMA on Jul 31, 2025 (≈ 194.552534 OLMA) would be worth
$2,227.63
+$1,227.63 (+122.8%) today · 2.23× · US Dollar
Based on a OLMA entry price of $5.14 vs. today's $11.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.7 | $978.63 | -2.1% |
| 1 month ago | $12.08 | $947.85 | -5.2% |
| 3 months ago | $14.32 | $799.58 | -20.0% |
| 6 months ago | $25.65 | $446.39 | -55.4% |
| 1 year ago | $5.14 | $2,227.63 | +122.8% |
| All time (5.0y) ago | $23.96 | $477.88 | -52.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OLMA forecast.
Our base-case forecast reaches $23.00 around 2040.
Implied market cap at $23.00: $2.01B
The multi-year forecast shows meaningful upside beyond the near term. For 2030 the average price is projected to be $13.76 with a min of $10.13 and a max of $20.16, yielding an ROI of 14.5% and a neutral sentiment. The 2040 outlook is substantially more bullish, with an average of $27.49, a min of $17.28, a max of $47.06, an ROI of 128.9%, and a bullish sentiment.
By 2050, the forecast indicates an average of $47.45, a min of $26.37, a max of $89.13, an ROI of 295.1%, and a bullish sentiment. The forecast table also shows intermediate years with gradual upside culminating in strong longer-term momentum. The asset’s near-term volatility is reflected in an annualized volatility of 50%, underscoring the uncertainty and the upside potential embedded in the longer horizon.
Tap a question to reveal the answer.
2030 forecast: min $10.13, avg $13.76, max $20.16, ROI 14.5%, sentiment NEUTRAL.
Near-term sentiment in 2026 is NEUTRAL with a forecast average price of $12.01 and ROI of 0%. There are positive ROIs in later years (e.g., 1.9% in 2027 and 12.2% in 2029), and strong upside in 2040 (128.9% ROI) and 2050 (295.1% ROI), but these are estimates and not guarantees.
Yes. The 2050 forecast shows a max price of $89.13, which exceeds $50.
Current price: $12.01. Market cap: $1.05B.
30-day range: $9.95 to $14.49.
Olema Pharmaceuticals, Inc. Community Discussion
0Share your Olema Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.